Dr. Lichter has served on Otonomy’s board of directors since May 2008. Dr. Lichter served as the company's chief executive officer from inception until November 2010. He is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early stage venture capital fund focused on information technology and life sciences.
In that role, he led Avalon’s investments in and served as a director and chief executive officer for privately held biotechnology companies Afraxis, Inc., Carolus Therapeutics, Inc., ReVision Therapeutics, Inc. and Zacharon Pharmaceuticals, Inc. He also currently serves on the board of directors of Aratana Therapeutics, Inc., a public company.
Dr. Lichter also led Avalon’s investments in or serves on the board of privately held companies Sova Pharmaceuticals, Inc., Avelas Biosciences, Inc., COI Pharmaceuticals Inc. and Sitari Pharmaceuticals Corp.
Dr. Lichter received a doctorate and bachelor’s degree in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.
President & CEO
President and CEO
2010 - Current (almost 7 years)
Aug, 2007 - Current (about 9 years)
Board & Advisor Roles (5)Update
|Aug, 2016||Avelas Biosciences||$20M / Series C||Avalon Ventures|
|Sep, 2014||Avelas Biosciences||$7.4M / Series B||Avalon Ventures|
|Apr, 2014||Otonomy||$49M / Series D||Avalon Ventures|
|Jan, 2014||Avelas Biosciences||$6.8M / Series B (Lead)||Avalon Ventures|
|Sep, 2013||Otonomy||$45.9M / Series C||Avalon Ventures|
|Dec, 2012||Avelas Biosciences||$7.65M / Series A (Lead)||Avalon Ventures|
|Dec, 2011||Aratana Therapeutics||$15M / Series B||Avalon Ventures|
|Jan, 2011||Aratana Therapeutics||$20M / Series A (Lead)||Avalon Ventures|
|Jun, 2010||Otonomy||$10M / Series A (Lead)||Avalon Ventures|
|May 20, 2016||PRNewswire All - Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company|
|Dec 11, 2015||UT San Diego - Otonomy's first drug approved|
|Dec 3, 2015||Xconomy - Avalon, TPG Lead $15M Deal to Advance Metformin as Cancer Drug|
|Jun 25, 2015||Bloomberg - The Promise and Peril of Crispr|
|Jun 15, 2015||Xconomy - Avalon Debuts Three More Tiny Biotechs In Risk-Share Deal With GSK|
|Jun 9, 2015||Bloomberg - With $500 Million Fund, Biotech Nears Venture Record|
|Apr 14, 2015||Xconomy - Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor|
|Mar 27, 2015||Xconomy - As Pharma Collaborations Gain Importance, GSK Opens Second Outpost|